13.07.2015 Views

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

chitosan and plga microspheres as drug delivery ... - UniCA Eprints

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

1. General Introductionremoval <strong>and</strong> limits their applicability. In the 1970s biodegradable polymers were suggested <strong>as</strong>appropriate <strong>drug</strong> <strong>delivery</strong> materials circumventing the requirement of removal (131). The ideaof polymer <strong>microspheres</strong> <strong>as</strong> <strong>delivery</strong> systems w<strong>as</strong> reported <strong>as</strong> early <strong>as</strong> the 1960s (132) <strong>and</strong>degradation w<strong>as</strong> incorporated by M<strong>as</strong>on et al. (133) through the employment of a degradablepolymer.Recent literature shows that suspensions of degradable <strong>microspheres</strong> can be employed forsustained <strong>drug</strong> rele<strong>as</strong>e at desirable doses. Biocompatibility can be achieved by the use ofnatural polymers such <strong>as</strong> cellulose, chitin, <strong>and</strong> <strong>chitosan</strong> or by the employment of semisynteticpolymers made from naturally occurring monomers such <strong>as</strong> lactic <strong>and</strong> glycolic acids.Polymers derived from synthetic monomers also show excellent <strong>delivery</strong> properties.However, their toxicity effects may require evaluation. The factors affecting <strong>drug</strong> rele<strong>as</strong>e arecontrollable; they are attributed to properties such <strong>as</strong> polymer molecular weight, <strong>as</strong> well <strong>as</strong>microsphere size, distribution, morphology <strong>and</strong> make-up.For preparation of <strong>microspheres</strong> using biodegradable polymers, it is important to choose anappropriate encapsulation process which meets the following requirements. First, thechemical stability <strong>and</strong> biological activity of the incorporated <strong>drug</strong>s should be maintainedduring the encapsulation process. For example, since most proteins are readily denatured uponcontact with hydrophobic organic solvents or acidic/b<strong>as</strong>ic aqueous solutions, the processshould avoid such harshenvironments. Second, the encapsulation efficiency <strong>and</strong> the yield of the microparticles shouldbe high enough for m<strong>as</strong>s production. Third, the microparticles produced should have there<strong>as</strong>onable size range. Fourth, the rele<strong>as</strong>e profile of the <strong>drug</strong> should be reproducible withoutthe significant initial burst. Fifth, the process employed should produce free-flowingmicroparticles, thus making it e<strong>as</strong>y to prepare uniform suspension of the microparticles. Thereare a number of techniques available for microencapsulation of <strong>drug</strong>s such <strong>as</strong> the emulsionsolventevaporation/extraction method, spray drying, ph<strong>as</strong>e separation-coacervation,interfacial deposition, precipitation method, in situ polymerization, etc. Each method h<strong>as</strong> itsown advantages <strong>and</strong> disadvantages. The choice of a particular technique depends on theattributes of the polymer <strong>and</strong> the <strong>drug</strong>, the site of the <strong>drug</strong> action, <strong>and</strong> the duration of thetherapy (134, 135, 136).Incre<strong>as</strong>ing or controlling the encapsulation efficiency (E%) is desirable, it can prevent the lossof precious medication <strong>and</strong> it can help to extend the duration <strong>and</strong> dosage of treatment. Yang etal. (137) have provided a revealing study which correlated the encapsulation efficiency to27

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!